At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]
NYS Entity Status
NYS Filing Date
SEPTEMBER 11, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - CAPITAL PLUS DEVELOPMENT, LTD.
Around the Web
- Near The East River, Plans Emerge For NY’s Next Life Science Center
By Ben Fidler - Monday Aug 21, 2017
- New Development: Soft in the Middle, Splashy Up Top
By STEFANOS CHEN - Friday Sep 15, 2017
The luxury market in New York is pulling in two directions, with developers betting on big-ticket palatial aeries and million-dollar “starter” homes.
- Behind an $18 Billion Donation to a New York Charity, a Shadowy Chinese Conglomerate
By MICHAEL FORSYTHE and ALEXANDRA STEVENSON - Wednesday Jul 26, 2017
A Chinese man has transferred more than 29 percent of HNA Group of China to a private foundation, adding to the questions about the firm’s structure and political connections.
- AI-enhanced mobile trading app raises $25 million from Eastern Europe
By Vitaly Bulatov - Wednesday Aug 2, 2017
Two major investors from Russia and Belarus have just invested $25 million in Capital.com, a trading app that is similar to Robinhood in the US or Trading212 in Europe — but with a specific AI-powered function that provides users with tailored content based on behavioral analysis.This is the fourth deal under a $100 million investment program targeting AI startups, which was announced in early 2017 by Larnabel VC and VP Capital. The first investments went to Astro Digital, a California-based startup which develops open APIs for satellite imagery, Banuba, a startup with...Read More
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]